The Chemo-Immunotherapeutic Roles of Tumor-Derived Extracellular Vesicle-Based Paclitaxel Delivery System in Hepatocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a novel nanodrug delivery system using tumor-derived extracellular vesicles (EVs) loaded with albumin-bound paclitaxel (PA). This EV-based system (EVPA) enhances chemo-immunotherapy for hepatocarcinoma, showing superior tumor-killing effects.
Area Of Science
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background
- Albumin-bound paclitaxel (PA) is a first-line chemotherapy for various cancers but shows low sensitivity and high toxicity in hepatocarcinoma treatment.
- Hepatocarcinoma cells exhibit innate resistance to PA, limiting its clinical efficacy and leading to severe side effects.
Purpose Of The Study
- To develop a novel nanodrug delivery system for improved hepatocarcinoma chemo-immunotherapy.
- To enhance the targeted delivery and therapeutic efficacy of albumin-bound paclitaxel (PA).
- To investigate the potential of tumor-cell-derived extracellular vesicles (EVs) as a drug delivery platform.
Main Methods
- Isolation and purification of ultraviolet (UV)-induced tumor-cell-derived extracellular vesicles (EVs) via differential centrifugation.
- Loading of albumin-bound paclitaxel (PA) into EVs through coextrusion to create the EVPA nanodrug delivery system.
- In vitro and in vivo evaluation of EVPA's targeting, immune activation, and anti-tumor effects in hepatocarcinoma models.
Main Results
- EVPA demonstrated superior tumor-killing effects compared to PA alone, both in vitro and in vivo.
- EVPA was effectively taken up by hepatocarcinoma cells and dendritic cells, activating specific immune responses.
- EVPA promoted the infiltration of CD4+ and CD8+ T cells into tumor tissues, enabling precise chemo-immunotherapy.
Conclusions
- The developed EVPA system offers a promising strategy for overcoming PA resistance in hepatocarcinoma.
- EVPA facilitates targeted drug delivery and combines chemotherapy with immunotherapy for enhanced anti-tumor activity.
- This nanodrug delivery system holds potential for improving the clinical treatment outcomes of hepatocarcinoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...